https://www.sickkids.ca/en/news/archive/2026/global-trial-supported-by-sickkids-stem-cell-research-shows-targeted-heart-drug-reduces-obstructive-hcm-in-youth/
Global trial supported by SickKids stem cell research shows targeted heart drug reduces obstructive...
A phase 3 clinical trial found that mavacamten can improve flow through the left ventricle, with the potential to spare some patients with hypertrophic...
stem cell researchheart drugglobaltrialsupported
https://www.biopharmadive.com/news/cytokinetics-fda-advisory-committee-vote-heart-failure/638762/
Cytokinetics heart drug voted down by FDA panel | BioPharma Dive
Following years of development, the biotech’s heart failure drug now faces another hurdle in its regulatory path forward, after a group of FDA advisers took...
heart drugfda panelcytokineticsvotedbiopharma
https://www.biopharmadive.com/news/cytokinetics-aficamten-acacia-results-non-obstructive-hypertrophic-cardiomyopathy/819266/
Cytokinetics heart drug scores in closely watched trial | BioPharma Dive
Myqorzo’s success in “non-obstructive” hypertrophic cardiomyopathy separates it from Bristol Myers Squibb’s rival Camzyos and opens up a multibillion-dollar...
heart drugcytokineticsscorescloselywatched
https://www.biopharmadive.com/news/novartis-tourmaline-acquire-deal-il-6-pacibekitug/759599/
Novartis to gain heart drug in $1.4B deal for Tourmaline Bio | BioPharma Dive
Tourmaline recently unveiled mid-stage trial data for its anti-inflammatory drug, which is ready for Novartis to advance into Phase 3 testing for heart disease.
heart drugnovartisgaindealtourmaline
https://keatonsplace.org/
Keaton's Place | The first stepping stone to your drug and alcohol recovery in the heart of North...
stepping stonealcohol recoverykeatonplacefirst
https://whiteheartlegal.com/
Defective Drug & Product Lawyer Network | White Heart Legal
Apr 9, 2026 - Hurt by a defective drug or product? You could be entitled to compensation. Learn more with a free case review and let our team get you on the road to recovery.
defective drugwhite heartproductlawyernetwork
https://www.statnews.com/2026/05/05/cytokinetics-myqorzo-non-obstructive-hypertrophic-cardiomyopathy-trial/
Cytokinetics drug hits dual goals in genetic heart disease study
May 5, 2026 - The drug, Myqorzo, is already approved for one form of the disease, and the new results, if cleared by regulators, could boost its sales.
heart diseasecytokineticsdrughitsdual